维普中文期刊产品整合服务

Multicenter Clinical Study for Evaluation of Efficacy and Safety of Transdermal Fentanyl Matrix Patch in Treatment of Moderate to Severe Cancer Pain in 474 Chinese Cancer Patients

查看全文 作　　者：Yu-lin [1]Zhu;Guo-hong [1]Song;Duan-qi [2]Liu;Xi [3]Zhang; Kui-feng [4]Liu; Ai-hua [5]Zang; Ying [6]Cheng; Guo-chun [7]Cao; Jun [8]Liang; Xue-zhen [9]Ma; Xin [10]Ding; Bin [11]Wang;Wei-lian [12]Li;Zuo-wei [13]Hu;Gang [14]Feng;Jiang-jin [15]Huang;Xiao [16]Zheng; Shun-chang [17]Jiao; Rong [18]Wu; Jun [1]Ren 高影响力作者 机构地区：[1]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education), Department of Breast Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China;[2]The PLA Military Genera/Hospital of Beijing, Beijing 100009, China;[3]No. 3 People's Hospital of Chengdu, Chengdu 610031, China;[4]The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, China;[5]Hubei Cancer Hospital, Wuhan 430079, China;[6]Jilin Cancer Hospital, Changchun 130012, China;[7]Jiangsu Cancer Hospital, Nonjing 210009, China;[8]The Affilicated Hospital of Medical College Qingdao University, Qingdao 266003, China;[9]Qingdao Cancer Hospital, Qingdao 266042, China [10]Shanghai Huaihai Hospital, Shanghai 200031, China;[11]Suzhou Municipal Hospital,Suzhou 215001, China;[12]Tianjin People's Hospital, Tianjin 300121, China;[13]Wuhan Integrated TCM & Western Medicine Hospital, Wuhan 30070, China;[14]Pu Ai Hospital of Wuhan City, Wuhan 430070, China;[15]Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310009, China;[16]Zhejiang Cancer Hospital, Hangzhou 310022, China;[17]The General Hospital of the People's Liberation Army, Beijing 100853, Chino;[18]Shengjing Hospital of China Medical University, 5henyang 110004, China高影响力机构 出　　处：《Chinese Journal of Cancer Research》索引2011年第23卷第4期,共6页高影响力期刊 摘　　要：Objective: Although a new matrix formulation fentanyl has been used throughout the world for cancer pain management, few data about its efficacy and clinical outcomes associated with its use in Chinese patients have been obtained. This study aimed to assess the efficacy and safety of the new system in Chinese patients with moderate to severe cancer pain. Methods: A total of 474 patients with moderate to severe cancer pain were enrolled in this study and were treated with the new transdermal fentanyl matrix patch (TDF) up to 2 weeks. All the patients were asked to record pain intensity, side effects, quality of life (QOL), adherence and global satisfaction. The initial dose of fentanyl was 25 ?g/h titrated with opioid or according to National Comprehensive Cancer Network (NCCN) guidelines. Transdermal fentanyl was changed every three days. Results: After 2 weeks. The mean pain intensity of the 459 evaluated patients decreased significantly from 5.63?1.26 to 2.03?1.46 (P<0.0001). The total remission rate was 91.29%, of which moderate remission rate 53.16%, obvious remission rate 25.49% and complete remission rate 12.64%. The rate of adverse events was 33.75%, 18.78% of which were moderate and 3.80% were severe. The most frequent adverse events were constipation and nausea. No fatal events were observed. The quality of life was remarkably improved after the treatment (P<0.0001). Conclusion: The new TDF is effective and safe in treating patients with moderate to severe cancer pain, and can significantly improve the quality of life. 关 键 词：Transdermal fentanyl matrix patch (TDF) Cancer pain EFFICACY Safety Quality of life
相关文献

参考文献(35)

引证文献(6)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费